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Background: The 2013 GOLD classification system for COPD distinguishes four stages: A (low symptoms, low
exacerbation risk), B (high symptoms, low risk), C (low symptoms, high risk) and D (high symptoms, high risk).
Assessment of risk is based on exacerbation history and airflow obstruction, whatever results in a higher risk
grouping. The previous system was solely based on airflow obstruction. Earlier studies compared the predictive
performance of new and old classification systems with regards to mortality and exacerbations. The objective of
this study was to compare the ability of both classifications to predict the number of future (total and severe)
exacerbations and mortality in a different patient population, and to add an outcome measure to the comparison:
lung function decline.
Methods: Patient-level data from the UPLIFT trial were used to analyze 4-year survival in a Weibull model, with GOLD
stages at baseline as covariates. A generalized linear model was used to compare the numbers of exacerbations (total
and severe) per stage. Analyses were repeated with stages C and D divided into substages depending on lung
function and exacerbation history. Lung function decline was analysed in a repeated measures model.
Results: Mortality increased from A to D, but there was no difference between B and C. For the previous GOLD
stages 2–4, survival curves were clearly separated. Yearly exacerbation rates were: 0.53, 0.72 and 0.80 for stages 2–4;
and 0.35, 0.45, 0.58 and 0.74 for A-D. Annual rates of lung function decline were: 47, 38 and 26 ml for stages 2–4 and
44, 48, 38 and 39 for stages A-D. With regards to model fit, the new system performed worse at predicting mortality
and lung function decline, and better at predicting exacerbations. Distinguishing between the sub-stages of high-risk
led to substantial improvements.
Conclusions: The new classification system is a modest step towards a phenotype approach. It is probably an
improvement for the prediction of exacerbations, but a deterioration for predicting mortality and lung function
decline.
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The Global initiative for chronic Obstructive Lung Disease
(GOLD) classification for severity of chronic obstructive
pulmonary disease (COPD) is used to classify individual
patients, describe study populations, monitor disease pro-
gression, and guide individual treatment decisions.
Consensus has grown that the previous GOLD classifica-
tion, which was entirely based on forced expiratory volume
in 1 second as percentage of the predicted value for some-
one of the same gender, age and height (FEV1%-predicted),
was an insufficiently reliable predictor of the variety of
manifestations of the disease [1-4]. For example, frequent
exacerbators are also found among patients with relatively
mild forms of airway obstruction [5]. This is important,
since exacerbations do not only predict future exacerba-
tions but are also a risk factor of faster disease progression
and mortality [6]. There have been pleas for a more explicit
recognition of the variety of COPD phenotypes which
should improve understanding of the impact of the disease
and, more importantly, provide prognostic information
and guide the selection of more appropriate therapies [7].
In 2011, GOLD presented a new classification system,
which was adapted slightly in 2013 [8]. This new classi-
fication distinguishes four groups of patients, based on
symptoms and exacerbation risk. The assessment of the
latter can be based on either exacerbation history or
degree of airflow limitation, whatever results in a
higher risk. Symptoms are to be assessed using either
the modified British Medical Research Council ques-
tionnaire (mMRC) [9], which measures breathlessness,
or the COPD Assessment Test (CAT) [10], which
provides a more comprehensive assessment of the
symptomatic impact of COPD.
Recently, several studies investigated the prognostic
value of the old and the new (2011/2013) systems with
regards to a number of outcome measures. Mortality was
predicted equally well by both systems in studies by
Soriano et al., Agustí et al. and Johannessen et al. [11-13],
whereas Leivseth et al. found that the old classification
performed better [14]. Exacerbations and hospitalisations
were predicted better by the new system according to
Lange et al. and Agustí et al. [12,15], but Johannessen
et al. saw no difference in performance between the
systems [13]. So far, only one study examined the ability
of the new system to predict lung function decline [12].
It did not find differences in predicted lung function
decline across severity stages. However, in this study no
comparison with the old system was made.
It is important that results from these studies are
replicated or contradicted in different populations.
Data from the “Understanding Potential Long-term
Impacts on Function with Tiotropium” (UPLIFT) trial
[16-18] provide the opportunity to investigate the
prognostic performance of the new classification systemwith four years of follow-up. This trial is especially suitable
for this purpose, not only because of its duration, but also
because of its size (almost 6,000 patients randomized),
international origin, and high quality-controlled lung
function data.
The aim of this study, therefore, was to compare the
ability of the old and the new (i.e. 2013) COPD classifica-
tion to predict future decline in lung function, mortality,
the total number of exacerbations and the number of
severe exacerbations.
Methods
Data
The UPLIFT trial was a multinational, randomized,
double-blind, placebo-controlled trial, investigating the
effect of tiotropium on the yearly rate of decline in FEV1
in ≥40 years old, currently or formerly smoking patients
(≥10 pack-years) with moderate to very severe COPD ac-
cording to the old GOLD classification system (stages 2
to 4, post-bronchodilator FEV1 of 70% or less of the pre-
dicted value) [16,17]. Key exclusion criteria were a history
of asthma, a COPD exacerbation or respiratory infection
within 4 weeks before screening, a pulmonary resection,
use of supplemental oxygen for more than 12 hours per
day, and coexisting illnesses that could preclude partici-
pation in the study or interfere with the study results.
Patients received either 18 μg of tiotropium or a match-
ing placebo once daily. All respiratory medications, except
other inhaled anticholinergic drugs, were permitted dur-
ing the trial. Smoking cessation programs were offered to
all patients before randomization.
Patients were recruited from 2003 to 2004 at 487 cen-
tres in 37 countries. The study protocol was approved by
the ethics committee at each centre, and all patients pro-
vided written informed consent [17]. The follow-up period
was four years, in which lung function, exacerbations, St.
Georges Respiratory Questionnaire (SGRQ) [19] and mor-
tality were recorded. Exacerbations were defined as an
increase in or the new onset of more than one respiratory
symptom (cough, sputum, sputum purulence, wheezing,
or dyspnoea) lasting three days or more and requiring
treatment with an antibiotic or a systemic corticosteroid,
and/or a hospitalisation. Patients were assessed at ran-
domisation, after one month, six months, and every six
months thereafter. For the base case analyses the data
from the two treatment groups (tiotropium and control)
were combined.
Data from 5630 patients were used in the analysis.
Mortality
Time to death was analysed in Weibull regression
models, with either the old or new GOLD classification
as covariates as well as other prognostic factors. These
were selected in an iterative backward selection process,
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excluded until all p-values were below 0.20. Candidates for
inclusion in the model were age, gender, body mass index
(BMI), smoking status and the presence or absence of
several co-morbidities (coronary heart disease, arrhythmia,
vascular disease, nervous disease, diabetes, depression and
anaemia).
The regression results were used to construct average ad-
justed survival curves, following the procedure proposed
by Hernàn [20]. First, the model coefficients were used to
fit multiple individual survival curves for each patient. Each
curve assumed a different GOLD stage, irrespective of the
actual classification of the patient. The other baseline char-
acteristics were kept constant within patients. After this,
mean survival probabilities per 6-month interval were
calculated over all patients for each stage and each point in
time. These probabilities were then used for constructing
survival curves per stage. This was done to assure that
differences in the curves would be due to different severity
stage assignments only, and not to other differences (e.g.
demographic differences) between the groups.
The models’ performance was compared by visually
inspecting the ranges over which 4-year mortality dif-
fered across stages, by using the Akaike Information
Criterion (AIC) for model fit [21] and by Harrell’s
c-statistic for the measure of discrimination across
stages [22,23]. A c-statistic of 0.5 means that a model has
no predictive discrimination, in other words, that it has a
50% chance of correctly predicting which of two subjects
in different risk categories has the highest probability of
experiencing the event. There is no universally used
interpretation of the value of the c-statistic. In the
context of logistic regression, Hosmer et al. consider
values of 0.7 to 0.8 to indicate acceptable discrimination,
while discrimination is considered excellent between 0.8
and 0.9 and outstanding when the c-statistic ≥0.9 [24].
The AIC is a measure to compare the goodness-of-fit
of different statistical models. Its absolute value has no
interpretation. A difference in AIC of ≥4 is often consid-
ered an indication that the model with the higher AIC
fits the data less well [25].
Exacerbations
Negative binomial regression with adjustment for treat-
ment exposure was applied to analyse the total rate of
exacerbations. The regression model contained either the
old or the new GOLD stages, as well as other prognostic
factors if necessary. In an iterative backward selection
process, the covariate with the highest p-value was
excluded from the model unless this led to a 10% change
in the estimate of the annual exacerbation rate [26].
The regression results were used to estimate mean
rates per GOLD stage. For each patient, the number of
exacerbations per year was predicted for each stage, giventhe patient’s characteristics but irrespective of the actual
classification of the patient, and assuming 365.25 days
per year. The individual predictions per disease stage
were then averaged over all patients.
The performance of the new model was compared with
that of the old model by visually inspecting the ranges
over which rates differed across stages and by using the
AIC for model fit. This was repeated for severe exacerba-
tions, which were defined as COPD exacerbations requir-
ing a hospital admission.
Lung function decline
Lung function decline, expressed as the deteriorating
course of post-bronchodilator FEV1, was analysed in a
linear random effects model. This analysis started at day
30 in order to take into account the fact that many
patients experienced an initial post-randomisation im-
provement in lung function. Covariates were days since
randomisation and interactions of GOLD stage and days.
These interactions were used to describe decline for each
stage. The intercepts and the slope for time since
randomisation were assumed to be random with an
unstructured covariance matrix and the interactions were
modelled as fixed effects. Patients with at least three
measurements from day 30 were included. The regres-
sion results were used to estimate mean annual lung
function decline per GOLD stage. The annual rate of
decline per disease stage was determined by multiplying
the regression coefficient for this stage by 365.25. The
selection of covariates took place along the same lines as
for exacerbations. The models’ performance was compared
by visually inspecting the ranges over which rates differed
across severities and by using the AIC for model fit.
Classification
Patients were classified into GOLD stage 2 to 4, based on
post-bronchodilator FEV1% predicted (50-70%, 30-50%,
<30%) and into GOLD stage A to D, based on the 2013
GOLD classification [8]. Patients were considered a high
risk for an exacerbation if they had a FEV1% predicted
<50%, or experienced at least two exacerbations in the
previous year, or had been admitted to the hospital with
an exacerbation at least once during the previous year.
The number of exacerbations in the year before
randomization was defined as the number of courses of
oral corticosteroids or antibiotics or the number of hos-
pitalisations, whichever was the highest.
Since the dataset did not contain CAT or mMRC scores,
on which the symptom dimension of the classification is
supposed to be based, the Saint Georges Respiratory
Questionnaire score (SGRQ) was used instead. The SGRQ
measures perceived well-being in COPD patients and the
impact of the disease on their activities. Patients with an
SGRQ score ≥25 were placed in the ‘high level’ symptoms
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have the strongest correspondence with the CAT thresh-
old ≥10 [27].
Substages
All analyses with the new GOLD classification were re-
peated with substages of C and D. Patients were assigned
to substages based on the reason for being considered
high-risk: FEV1% predicted <50% but no history of
frequent exacerbations (C1 and D1), history of frequent
exacerbations but FEV1% predicted ≥50% (C2 en D2), or
FEV1% predicted <50% combined with a history of
frequent exacerbations (C3 en D3).
All analyses were performed in Stata 12.1 [28]. Confi-
dence intervals were calculated by bootstrapping with
1000 replications [29,30].
Sensitivity analyses
All analyses were repeated with a different threshold for
symptom severity: SGRQ ≥39. This value was found by
Han et al. to have the strongest correspondence with the
mMRC threshold of 2 [27].
Furthermore, the analyses with the SGRQ ≥25 thresh-
old were repeated in the control group separately.
Results
Patient characteristics
Table 1 describes the distribution of the patients across
old and new GOLD stages. Patients from stage 2 were
classified into all four new stages, with the majority in B.
Almost all stage 3 and stage 4 patients were classified
into stage D.
The baseline characteristics of the patients, divided by
the new GOLD stages are presented in Table 2. The lar-
gest group is formed by patients in stage D. GOLD B
contained the highest proportion of current smokers.
The time since diagnosis was the longest for D. AirwayTable 1 Distribution of patients from stages 2-4 into stages A
GOLD 2
n = 2611 (46% of total)
A 356 (14% of GOLD2)
B 1421 (54%)
C 89 (3%)
D 745 (29%)
C1* -
C2* 89 (3%)
C3* -
D1*
D2* 745 (15%)
D3*
*C1/D1, high risk is based on FEV1<50% only; C2/D2, based on history of frequent exacobstruction was similar for A and B, and for C and D.
The number of different types of respiratory medications
and the number of courses of antibiotics and oral ste-
roids in the year before randomisation increased from A
through D. Patients in A and B had not been admitted
to the hospital in the year before randomisation.
Mortality
The covariates in the final model were age, sex, BMI,
smoking status and the presence of the comorbidities
coronary heart disease, vascular disease, diabetes and de-
pression. The adjusted survival curves for each GOLD
stage, adjusted for age, sex and selected co-morbidities
are presented in Figures 1 and 2, for the old and the
new classification, respectively.
Mortality increases with stage in both systems. However,
all differences between stages were statistically significant
at the 1%-level for the old classification, while in the new
system only the difference between C and D was signifi-
cant. The curves for B and C almost overlap (p = 0.67).
Their distances to stage A are borderline significant
(p = 0.08). After 4 years, 7.4% of patients in GOLD A
had died, compared to 18.8% in GOLD D. These pro-
portions were further apart for the old stages 2 and 4:
10.7% and 33.5%, respectively.
Table 3 shows that Harrell’s c-statistics for discrimina-
tive performance were similar for all three classification
systems. All models had a discrimination that falls slightly
short of being acceptable, in the interpretation of Hosmer
et al. [24]. The best model fit, as measured by the AIC,
was achieved for the old model. This was true in over 99%
of the bootstrap replications.
Figure 3 shows that there were important differences in
predicted mortality across substages of D. Patients in
substages with a strongly diminished lung function (D1
and D3) were more likely to die than those in D2 (p <
0.01). Being at high risk for exacerbations added relatively-D and substages C1-D3
GOLD 3 GOLD 4
n = 2529 (45% of total) n = 490 (9% of total)
- -
- -
195 (8%) 12 (2%)
2334 (92%) 478 (98%)
147 (6%) 6 (1%)
- -
48 (2%) 6 (1%)
1317 (52%) 246 (50%)
-
1017 (40%) 232 (47%)
erbations only; C3/D3, based on both.
Table 2 Baseline characteristics of patients in GOLD stages
GOLD A GOLD B GOLD C GOLD D P-value*
(n = 356, 6%) (n = 1421, 25%) (n = 296, 5%) (n = 3557, 63%)
Age 64.9 64.6 64.6 64.5 0.796
Male 81.4% 72.7% 85.8% 73.2% <0.001
BMI 25.9 26.9 25.7 25.7 <0.001
Current smoker 29.2% 34.3% 24.0% 28.5% <0.001
Pack-years 37.7 40.4 37.8 40.7 0.076
Time since diagnosis (years) 9.2 9.4 9.2 10.0 0.030
FEV1 (liters) 1.72 1.63 1.33 1.16 -
FEV1 (as a% of predicted) 60.3% 58.6% 46.5% 41.9% -
SGRQ 17.1 44.9 18.4 51.3 -
Respiratory medication at baseline (%)
Short-acting anticholinergic 28.4% 39.4% 40.2% 50.3% <0.001
Long-acting anticholinergic 2.5% 1.6% 1.7% 2.0% 0.664
Short-acting β2-agonist 55.1% 62.5% 60.5% 73.9% <0.001
Long-acting β2-agonist 44.9% 52.2% 58.8% 64.1% <0.001
Inhaled corticosteroid 47.8% 54.7% 64.5% 66.0% <0.001
Oral corticosteroid 2.5% 4.6% 4.7% 11.0% <0.001
Theophylline compound 14.6% 21.0% 23.6% 31.9% <0.001
Mucolytic agent 3.1% 5.6% 4.7% 8.3% <0.001
Leuktriene-receptor antagonist 1.1% 2.0% 1.4% 4.3% <0.001
Supplemental oxygen 0% 0.6% 1.4% 3.0% <0.001
Number of different types of medication 1.75 2.04 2.24 2.52 <0.001
Number of co-morbidities 3.32 3.71 3.03 3.71 0.588
Number of courses of antibiotics 0.21 0.28 1.08 1.43 -
Number of courses of oral corticosteroids 0.097 0.146 0.55 0.91 -
Number of hospital admissions in previous year 0 0 0.21 0.37 -
*Differences were tested using anova or χ2 test.
Figure 1 Model-based adjusted survival curves, per GOLD
stage 2, 3 and 4.
Figure 2 Model-based adjusted survival curves, per GOLD
stage A, B, D and D.
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Table 3 Weibull models for mortality
Classification system C-statistic AIC
GOLD stage 2 to 4 0.6936 5644.299
GOLD stage A to D 0.6755 5709.177
GOLD stage A, B, C1 to C3 and D1 to D3 0.6861 5693.128
Harrell’s c-statistic and Akaike’s Information Criterion.
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ference in mortality was found.
Exacerbations
The final regression models for the total number of ex-
acerbations and for the number of severe exacerbations
contained GOLD classification as the sole covariate.
Table 4 shows the annual exacerbation rates for patients
classified into the GOLD groups. The exacerbation rate
increased with disease severity in both the old and the new
system. The rates in the new classification covered a broader
range than the rates in the old stages and the new classifica-
tion system had a much better AIC than the old system.
The exacerbation rates varied widely between the sub-
stages of C and D. While the exacerbation rate in C1
(no history of frequent exacerbations) was similar to the
rate in B, patients in C3 (low lung function and history
of frequent exacerbations) experienced more exacerba-
tions than patients in D overall. Symptoms, lung func-
tion and exacerbation history were all related to the
exacerbation rates.
The patterns are less clear for severe exacerbations
(Table 5). The old stages showed a broader range of rates
than the new stages. Substages C3 and D3 had the high-
est number of severe exacerbations, although C3 did not
differ from D overall.
Lung function decline
The final regression models contained disease severity as
the sole covariate. Overall, stages with relatively goodFigure 3 Model-based adjusted survival curves, per substage of
GOLD C and D.lung function at baseline showed a faster decline over
the course of the trial (see Table 6). The predicted an-
nual rates of decline covered a broader range for the
model with the old stages 2, 3 and 4 than for the model
with stages A, B, C and D. Furthermore, the model with
the old classification had the best fit in terms of the
AIC. The models with the new GOLD classification with
and without the substages had a similar fit. The substage
of patients who started the trial with a relatively good
lung function, C2 and D2, experienced a decline that
was comparable to stages A and B. The other substages
had stronger declines.
Sensitivity analyses
The results of the sensitivity analyses are presented in the
Additional file 1. The same patterns in relative predictive
power can be seen as in the base case analyses. Using the
SGRQ ≥ 39 threshold, however, led to improvement of all
AICs for the new classification system.
Similarly as to what was found in the base case analysis,
all three mortality models had very similar c-statistics
(Additional file 1: Table S1). In contrast with the primary
analysis, the best AIC was achieved by the new mortality
model with substages. The old and new classification
models had the same fit.
The predicted exacerbation rates in the new classification
covered a broader range than the rates in the old classi-
fication (Additional file 1: Tables S2 and S3). The new
classification system also had a much better AIC than
the old system, and the AIC for the new classification
with substages was even better. Predicted exacerbation
rates were slightly higher when the SGRQ ≥ 39 thresh-
old was used.
With regard to lung function (Additional file 1: Table
S4), annual decline rates covered a broader range for the
old model, which also had the best AIC. Rates of lung
function decline were not different for different SGRQ
thresholds.
When the analyses with the original threshold were
repeated on the control group separately, similar patterns
were found (see Additional file 1: Table S5). For severe
exacerbations, the best fit was achieved by models with
the new system with the new classification system with
substages. For mortality and lung function the best fit was
achieved by models with the old classification system.
Discussion
This study compared the prognostic performance of the
old and new GOLD classifications for COPD regarding
mortality, exacerbations and decline in lung function.
The findings depend on the outcome measure.
As for mortality, both classification systems discriminated
equally well, but the old model performed better in terms
of model fit. The loss of information on lung function,
Table 4 Annual rate of exacerbations (95% confidence interval), per GOLD
Old stage P-value* New stage P-value* Substage P-value*
2 0.53 (0.50 - 0.55) - A 0.35 (0.29 - 0.41) - C1 0.47 (0.39 - 0.57) -
3 0.72 (0.69 - 0.76) <0.001 B 0.45 (0.42 - 0.48) 0.001 C2 0.55 (0.41-0.71) 0.37
4 0.80 (0.72 - 0.89) 0.09 C 0.58 (0.51 - 0.68) 0.001 C3 0.96 (0.70-1.24) 0.06
D 0.74 (0.71 - 0.77) 0.001 D1 0.56 (0.53-0.60) -
D2 0.75 (0.69-0.81) <0.001
D3 0.97 (0.92-1.04) <0.001
AIC 22,697.09 22,571.27 22,417.35
*Wald test of difference with category immediately above. Overall Wald test of equal rates across stages: p < 0.001 for all models. C1/D1: classified in C/D because
of lung function impairment; C2/D2: in C/D because of exacerbation history; C3/D3: because of lung function and exacerbation history.
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does not appear to have been completely mitigated by the
added information on symptoms and exacerbation history
in the new system.
With regard to (severe) exacerbations, all three dimen-
sions of the new GOLD classification strongly contributed
to the predictions. This led to a much better performance
for the new classification system than for the old system.
With regard to lung function decline, however, the pre-
dictive power of the old system was much better. Infor-
mation on symptom level and exacerbation history did
not improve the ability to predict decline of FEV1.
Our study is the first to compare the old and new sys-
tem’s ability to predict lung function decline. Agusti et al.
did assess the decline across the new stages [12] but did
not compare the two classification systems. Furthermore,
they did not find significant differences in decline, whereas
patients with a worse lung function in our data showed a
slower decline. This pattern was less clear in the new
system than in old system, but still clear and statistically
significant. Combining patients with a low lung function
and history of frequent exacerbations into the same stages
hides the major differences between these patients. This
was also observed in earlier studies [12,15]. Dividing the
stages into substages, depending on the reason for which
patients are considered high-risk, is very informative and
could improve recommendations in individual treatment
decisions and in the preparation of treatment guidelines.Table 5 Annual rate of severe exacerbations (95% confidence
Old stage P-value* New stage
2 0.18 (0.16 - 0.20) - A 0.08 (0.05 – 0
3 0.39 (0.36 - 0.42) <0.001 B 0.14 (0.12 – 0
4 0.54 (0.46 - 0.62) <0.001 C 0.21 (0.16 – 0
D 0.40 (0.37 – 0
AIC 16,019.57 15,859.22
*Wald test of difference with category immediately above. Overall Wald test of equ
of lung function impairment; C2/D2: in C/D because of exacerbation history; C3/D3:The aim of the new guidelines is to enhance the under-
standing of the impact of COPD on individual patients
by combining ‘the symptomatic assessment with the
patient’s spirometric classification and/or risk of exacer-
bations’ [8]. Although lung function in itself does not
have a direct impact on patients – it only does so through
symptoms, exacerbation risk and mortality risk – it still
is an important aspect of disease severity, and hence of
the new classification system, because it is a better
predictor of mortality than symptoms and exacerbations.
Using trial data for a study like this has advantages and
disadvantages. Among the advantages is the high quality
of the spirometry data because of there was a good qual-
ity control system in place. A disadvantage is that a trial
population shows less variation in patient and disease
characteristics than a real-life population because of the
in- and exclusion criteria. Furthermore, the exacerbation
rate in the UPLIFT trial was relatively low. Despite this
we found that the new classification system was clearly
better in predicting exacerbations than the old classifica-
tion system.
For all analyses we combined the data from the two
treatment groups in the UPLIFT trial. We performed add-
itional analyses with treatment as a covariate. This did not
lead to different conclusions.
A limitation of this study is that our data contained no
information on the mMRC or CAT scores, which are the
recommended ways of establishing symptom severity ininterval), per GOLD stage
P-value* Substage P-value*
.12) - C1 0.18 (0.12 – 0.25) -
.17) <0.001 C2 0.17 (0.08 – 0.28) 0.71
.27) <0.001 C3 0.37 (0.18 – 0.57) 0.001
.43) <0.001 D1 0.30 (0.27 – 0.33) -
D2 0.30 (0.26 – 0.36) 0.85
D3 0.59 (0.53 – 0.65) <0.001
15,634.93
al rates across stages: p < 0.001 for all models. C1/D1: classified in C/D because
because of lung function and exacerbation history.
Table 6 Annual rates of lung function decline in millilitres, (95% confidence intervals), per GOLD stage
Old stage P-value* New stage P-value* Substage P-value*
2 47 (44–50) - A 44 (38–52) - C1 32 (23–42) -
3 38 (36–41) <0.001 B 48 (45–52) 0.29 C2 47 (33–60) 0.11
4 26 (21–31) 0.002 C 38 (30–45) 0.01 C3 38 (16–53) 0.43
D 39 (37–42) 0.74 D1 36 (33–39) -
D2 46 (40–52) 0.003
D3 38 (34–42) 0.04
AIC −30,229.05 −30,209.08 −30,212.52
*Wald test of difference with category immediately above. Overall Wald test of equal decline across stages: p < 0.001 for all models. C1/D1: classified in C/D
because of lung function impairment; C2/D2: in C/D because of exacerbation history; C3/D3: because of lung function and exacerbation history.
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http://www.biomedcentral.com/1471-2466/14/163COPD patients. However, SGRQ and CAT are highly
correlated [31]. According to the authors of the new
GOLD guidelines, ‘the crucial aspect is to consider
whether the patient has only trivial symptoms or feels
significantly limited by them’ [32]. Several scales can be
used for that purpose. In fact, the authors note that
updates of the guidelines may include other scales.
Nevertheless, different scales may lead to different
categorisations. The currently proposed cut-off points
of the CAT and mMRC do not lead to exactly the same
classification of patients [27,33]. More specifically,
patients were 25% less likely to be classified as C in-
stead of D when the mMRC criterion was applied [27].
The current CAT cut-off point of 10 or more appears
to be more in line with a mMRC score of 1 instead of 2
[27,34].
Earlier studies based the categorisation on the
mMRC ≥2 [11-15]. Overall, their findings are in line
with ours, using SGRQ ≥25 as a surrogate for CAT
≥10. Furthermore, we found similar results when we
used a higher SGRQ threshold as a surrogate for
mMRC ≥2 in the comparison of the old and new classi-
fication. This is consistent with the guideline statement
that does not attach particular importance to the
choice for a specific symptom scale. Nevertheless, the
model fit was better when the higher SGRQ threshold
was used.
In summary, in the UPLIFT population of moderate
to very severe COPD patients, the 2013 GOLD classifi-
cation performed better than the old classification
when predicting future exacerbations, whereas the old
classification system performed equally well or better
when predicting mortality and lung function decline.Conclusion
Combining our results in the UPLIFT data with those
from earlier studies in different patient populations leads
to the conclusion that the new classification system is a
modest step towards a phenotype approach. The new
system is probably an improvement for the prediction ofexacerbations, but a step back with regards to predicting
mortality and lung function decline.
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